Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

McDonald, K; Nozue-Okada, K; Khasraw, M

Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

conference contribution

posted on 2024-06-13, 09:18 authored by K McDonald, K Nozue-Okada, M Khasraw

Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

History

Volume

74

Location

San Diego, Calif.

Publisher DOI

https://doi.org/10.1158/1538-7445.AM2014-3777

Start date

2014-04-05

End date

2014-04-09

ISSN

0008-5472

eISSN

1538-7445

Language

English

Publication classification

E3.1 Extract of paper

Title of proceedings

Proceedings of the AACR Annual Meeting 2014

Event

American Association for Cancer Research. Conference (2014 : San Diego, Calif.)

Issue

19

Publisher

American Association for Cancer Research

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology 111299 Oncology and Carcinogenesis not elsewhere classified 970111 Expanding Knowledge in the Medical and Health Sciences

Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

History

Volume

Location

Publisher DOI

Start date

End date

ISSN

eISSN

Language

Publication classification

Title of proceedings

Event

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports